Immunotherapy
Finding ways to stimulate the body's immune system to help attack cancer cells is a growing area of research at The Institute of Cancer Research.
Clinical trials led by the ICR and our hospital partner The Royal Marsden have shown that the immunotherapy drug pembrolizumab can help extend the lives of some patients with advanced head and neck cancer, and prostate cancer.
The use of 'oncolytic' viruses, which can kill cancer cells both directly and by directing the immune system against them, is also an exciting area of research being explored by ICR researchers.
This page highlights recent news stories, blog posts and videos that concern immunotherapy research at the ICR.
Related pages
Latest ICR News
Innovative dual treatment shows promise in tackling deadly cancer
A new study has revealed a promising therapeutic strategy for pancreatic cancer, offering new hope for people living with this disease.
Athena Swan Silver renewal recognises ICR’s continued progress in fostering an inclusive research culture
The Institute of Cancer Research has been granted an Athena Swan Silver Award for a further four years, in recognition of the ICR’s continued progress in embedding gender equality and fostering an inclusive research culture.